Susana GarcÃ-a-Cerro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5310948/publications.pdf

Version: 2024-02-01

16	364	933447 10	940533 16
papers	citations	h-index	g-index

17	17	17	595
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome. PLoS ONE, 2014, 9, e106572.	2.5	81
2	Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. Neurobiology of Disease, 2017, 106, 76-88.	4.4	72
3	Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. Journal of Neuroinflammation, 2017, 14, 261.	7.2	42
4	Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. Neurochemical Research, 2016, 41, 2904-2913.	3.3	30
5	Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. Brain, Behavior, and Immunity, 2018, 73, 235-251.	4.1	21
6	Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice. Journal of Nutrition, 2020, 150, 1631-1643.	2.9	16
7	Decreasing the Expression of GABAA Î±5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome. Molecular Neurobiology, 2018, 55, 4745-4762.	4.0	15
8	Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome. Behavioural Brain Research, 2017, 334, 142-154.	2.2	14
9	Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene. Neurobiology of Disease, 2018, 110, 206-217.	4.4	14
10	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naÃ¯ve first-episode schizophrenia patients. Journal of Psychiatric Research, 2017, 95, 91-101.	3.1	12
11	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. Translational Psychiatry, 2018, 8, 276.	4.8	12
12	Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 613211.	3.5	12
13	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. Journal of Psychiatric Research, 2020, 126, 8-18.	3.1	9
14	Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice. Journal of Nutrition, 2020, 150, 2478-2489.	2.9	7
15	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. Psychopharmacology, 2020, 237, 2151-2159.	3.1	4
16	Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome. Nutritional Neuroscience, 2020, , 1-13.	3.1	3